#China #Shanghai #Biologics #AsymBio #Asymchem Group

AsymBio Breaks Ground on New R&D Facility in Shanghai

In a significant milestone for the biopharmaceutical industry, AsymBio, a subsidiary of the Asymchem Group, has officially started construction on a new research and development (R&D) facility located in Shanghai's Fengxian district. This project, commenced in May 2026, is poised to enhance AsymBio’s capabilities as a Contract Development and Manufacturing Organization (CDMO) focusing exclusively on biologics. The new eight-story building will occupy around 2,500 square meters and provide nearly 20,000 square meters of total floor space. It is expected to be fully completed and operational by the second half of 2027.

The Fengxian R&D building represents a crucial development in strengthening AsymBio’s position in the biopharmaceutical market by creating a full lifecycle, one-stop shop for biologics services. Located strategically adjacent to existing clinical and commercial manufacturing facilities for antibodies and antibody-drug conjugates (ADCs), the new structure is designed to support various essential processes including cell line development, upstream and downstream process development, conjugation process development, and drug product development, supplemented by a range of analytical development services.

One of the key features of this new facility will be its support of the Accelerated PCC (AccPCC) platform. This innovative R&D acceleration system is set to connect early-stage research and development (R&D) with clinical evaluation, effectively facilitating faster transitions from lead compounds to preclinical candidate selections. By utilizing a comprehensive, AI-enabled workflow, the AccPCC platform offers global biotech partners a full spectrum of technical assistance, encompassing lead optimization, developability assessments, and customized strategies for Clinical Manufacturing and Controls (CMC).

Rui Yang, CEO of AsymBio, stated, "Effective biologics development requires earlier engagement, integrated decision-making, and manufacturability considerations from the outset. By leveraging cross-site R&D resources across the entire Asymchem Group, AccPCC is designed to improve development efficiency and assist our clients in navigating complex programs with clarity and confidence."

With the construction of the Fengxian R&D facility, AsymBio aims to ensure that their operational framework is closely intertwined with manufacturing capabilities, streamlining the scale-up processes while shortening overall project timelines. The establishment of this site not only enhances AsymBio’s portfolio but also reinforces Shanghai's reputation as a hub for biopharmaceutical innovation.

AsymBio’s focus is entrenched in delivering comprehensive CDMO services, capitalizing on its parent company Asymchem Group's three decades of experience in the industry. With expertise spanning from early-stage research to large-scale manufacturing, AsymBio is committed to supporting advancements in biotherapeutics, including its work with monoclonal, bispecific and multispecific antibodies, alongside protein therapeutics and antibody drug conjugates.

This new R&D building is set to embody a commitment to sustainability as it will be constructed following stringent green and low-carbon construction standards. The initiative is reflective of the growing awareness and integration of environmental considerations within the biopharmaceutical sector, aligning with global trends toward sustainability and eco-friendly practices.

AsymBio's new facility stands as a beacon of progress, promising to deliver cutting-edge solutions to the biopharmaceutical industry while addressing the ever-increasing demand for efficient, integrated biologics services. As it gears up for full operations, the Fengxian R&D facility is expected to enhance collaboration among research teams and improve development pathways, ultimately contributing to faster and more efficient pathways for drug development in the global biopharmaceutical landscape.